Skip to search formSkip to main contentSkip to account menu

repaglinide

Known as: Repaglinida, repa-glinide, Repaglinidum 
A nonsulfonylurea insulin secretagogue belonging to the melgitinide class with hypoglycemic activity. Repaglinide is rapidly absorbed and has a rapid… 
National Institutes of Health

Related topics

Related topics

15 relations

Narrower (4)

AG-EE 388 ZWAG-EE 623 ZWPrandiMetPrandin

Broader (3)

CarbamatesHypoglycemic AgentsPiperidines
Diabetes Mellitus, Insulin-DependentDiabetes Mellitus, Non-Insulin-DependentDiabetic KetoacidosisDrug Allergy

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
Objective Organic anion transporting polypeptide 1B1 (OATP1B1), encoded by SLCO1B1, is an influx transporter expressed on the… 
Highly Cited
2004
Highly Cited
2004
Detection of anti-diabetics in equine plasma and urine by liquid chromatography-tandem mass spectrometry.
Review
2002
Review
2002
The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
2001
2001
Repaglinide-induced factitious hypoglycemia.
We report the first case of repaglinide-induced factitious hypoglycemia in a young male. This case posed a challenging diagnostic… 
Review
2000
Review
2000
Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
Type 2 diabetes mellitus is characterised by abnormal beta-cell function (present at the time of diagnosis) that is often… 
Highly Cited
2000
Highly Cited
2000
Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
OBJECTIVE This multicenter open-label clinical trial compared the efficacy and safety of repaglinide/troglitazone combination… 
Review
2000
Review
2000
A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of Type 2 diabetes
Repaglinide is a novel insulin secretagogue that was developed as a prandial glucose regulator for the treatment of people with… 
Review
1999
Review
1999
The use of insulin secretagogues in the treatment of type 2 diabetes.
Review
1998
Review
1998
Management of Antidiabetic Medications in Overdose
The drugs used to treat diabetes mellitus are diverse and involve several classes. However, these drugs can be roughly separated… 
1996
1996
Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets.
The meglitinide analogue repaglinide is a novel non-sulphonylurea insulinotropic agent which, like hypoglycaemic sulphonylureas… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)